23 August 2024 in Journal of Drug Delivery Science and Technology
15 March 2024 in Journal of Drug Delivery Science and Technology
18 September 2023 in Journal of Drug Delivery Science and Technology
13 January 2024 in International Journal of Pharmaceutics
12 January 2024 in Journal of Drug Delivery Science and Technology
29 July 2024 in Therapeutic Delivery
Sphingolipids (SL) are well recognized for their cell signaling through extracellular and intracellular pathways. Based on chemistry different types of SL are biosynthesized in mammalian cells and have specific function in cellular activity. SL has an ampiphilic structure with have hydrophobic body attached to the polar head enables their use as a drug delivery agent in the form of nanocarriers. SL-based liposomes can improve the solubility of lipophilic drugs through host and drug complexes and are more stable than conventional liposomal formulations. Preclinical studies of SL nanocarriers are reported on topical delivery, oral delivery, ocular delivery, chemotherapeutic delivery, cardiovascular delivery and Alzheimer's disease. The commercial challenges and patents related to SL nanoformulations are highlighted in this article.